Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled molgramostim versus placebo in adults with autoimmune pulmonary alveolar proteinosis
NL-OMON55020Phase 3Withdrawn
- Sponsor
- Parexel
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune pulmonary alveolar proteinosis (aPAP) comparing Molgramostim with Placebo (2 arms). Primary endpoint: Change in percent predicted DLCO from baseline to Week 24. Planned start Oct 2020; status: withdrawn.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NL-OMON55020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55020.